Flucess

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flucess

Property Description
Active Ingredient Fluconazole
Form Capsule, tablet, oral suspension, solution for injection
Pharmacological Class Systemic Antifungal Agent
Common Use (General) Management of fungal infections
Origin Synthetic Triazole derivative

The Fundamental Identity of Flucess (Fluconazole)

Flucess is a medicine designated as a Systemic Antifungal Agent used to manage infections caused by various types of fungi throughout the body. The primary active ingredient in Flucess is Fluconazole, a substance belonging to the antimycotic drug class.

This medication functions as a synthetic triazole derivative, making it a chemically synthesized pharmaceutical compound rather than one derived from natural sources. As a prescription (Rx) medicine, Flucess is positioned for use in patient groups where systemic absorption is critical for therapeutic success. Its fundamental purpose is to selectively interfere with the growth and multiplication of pathogenic fungi, providing a therapeutic option for infections that require treatment beyond the skin's surface.


Composition, Origin, and Available Forms

The core active substance is Fluconazole, a bis-triazole compound whose chemical classification is consistent across authoritative pharmacological databases. This synthetic ingredient is utilized in Flucess as a single-ingredient product. The Flucess oral suspension often includes specific flavoring to improve patient compliance, particularly in patient groups facing difficulty with administration.

Fluconazole is presented in several common drug forms, including capsules, tablets, an oral suspension, and a solution intended for intravenous injection. Consequently, the medicine is administered through two main routes: oral (by mouth) or intravenous (directly into the bloodstream).


General Therapeutic Purpose of this Antifungal

The general therapeutic purpose of Flucess is to halt the progression of fungal infections by incapacitating the pathogen at a cellular level. It achieves this by exerting a fungistatic action, which means it stops the infectious fungus from multiplying and spreading within the body.

This function is critical because it gives the body the opportunity to suppress and ultimately clear the underlying mycosis. Flucess provides a broad-spectrum approach to managing persistent or deep-seated fungal pathogens that require powerful systemic treatment.

Regulatory References

  1. Fluconazole: MedlinePlus Drug Information

What side effects are possible with Flucess?

The official safety profile for Flucess (Fluconazole) is structured by governmental health authorities to categorize and communicate all documented adverse reactions and safety characteristics, strictly excluding clinical advice or usage instructions.


Adverse Reaction Classifications

Adverse effects are formally grouped by frequency and the body system affected (System-Organ Class or SOC). The most frequently documented reactions include Headache, which is classified as Very Common (ge 1/10), and a group of effects classified as Common (ge 1/100 to < 1/10).

Common adverse reactions include gastrointestinal disturbances such as nausea, vomiting, abdominal pain, and diarrhea, as well as skin rash and elevations in liver enzyme levels (ALT, AST, alkaline phosphatase). Uncommon effects include dizziness, insomnia, and hypokalemia.


Serious Adverse Reactions and Safety Constraints

The regulatory label explicitly identifies specific Serious Adverse Reactions. These rare, severe events include potentially fatal hepatic toxicity (liver failure) and life-threatening severe cutaneous reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis. Additionally, the drug is associated with changes in the heart's electrical activity, specifically QT interval prolongation and the risk of the severe arrhythmia Torsade de pointes.

Safety constraints noted in regulatory documents include the medication's effect as a potent inhibitor of certain Cytochrome P450 enzymes (CYP2C9, CYP2C19, and moderate inhibition of CYP3A4), which is an important consideration in assessing the safety of co-administered medicines. Monitoring of liver function tests is specified for patients during treatment.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents describe the potential for serious clinical manifestations in cases of Flucess (Fluconazole) overdose, which necessitate immediate medical intervention.

Property Official Regulatory Statement
Documented Overdose Presentations Psychiatric manifestations, including hallucination and paranoid behavior, have been reported in overdosage cases.
Serious / Life-Threatening Outcomes The medicine is associated with QT interval prolongation and the risk of the serious arrhythmia Torsade de Pointes (TdP). Seizures have also been reported.
Emergency-Response Statements Overdose management requires the institution of symptomatic treatment with supportive measures. Gastric lavage may be used if clinically indicated.
Antidote Status No specific antidote is known; treatment focuses solely on supportive care and elimination.

In the event of an overdose or suspected overdose, immediate medical attention must be sought due to the risk of severe neurological and cardiac effects. Because Fluconazole is cleared predominantly by renal excretion, patients with impaired renal function may have reduced drug clearance. Regulatory information specifies that a 3-hour hemodialysis session decreases plasma concentrations by approximately 50%, establishing this procedure as an option for enhancing drug elimination.

Therapeutic Uses of Flucess

Flucess: Main Uses and Benefits


Flucess is prescribed for the treatment of various fungal infections throughout the body. The medication's primary therapeutic domain involves addressing conditions caused by the Candida species of fungus, also known as candidiasis.

Key applications of Flucess include the treatment of:

  • Vaginal candidiasis (yeast infection).
  • Oropharyngeal candidiasis (thrush, or yeast infection of the mouth and throat).
  • Esophageal candidiasis (infection of the tube connecting the mouth to the stomach).
  • Systemic Candida infections, which involve the bloodstream or other vital organs.

Additionally, Flucess is an established treatment for cryptococcal meningitis, a serious fungal infection that affects the membranes covering the brain and spinal cord. It also plays a role in infection prophylaxis, or prevention, particularly for patients undergoing procedures such as bone marrow transplantation who are at increased risk of developing candidiasis.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who can and cannot use Flucess? — Official Regulatory Information

The eligibility profile for Flucess (Fluconazole) is defined by absolute contraindications, organ function, and physiological state, based strictly on government regulatory documents.


Eligibility Scope Official Regulatory Statements
Contraindicated Populations Must not be used in patients with known hypersensitivity to Fluconazole or other Azole antifungals. Use is also prohibited if the patient is taking specific medications, such as Cisapride, Pimozide, or Erythromycin, due to the risk of serious cardiac events.
Age-Group Eligibility The medicine is approved for adults and has established use in adolescents, children, and neonates (infants leq 27 days old), although specific indications like genital candidiasis are not established in children.
Organ Function Restrictions Conditional use applies to patients with severe renal impairment, who require a reduction in the prescribed multi-dose amount to maintain eligibility. Use in patients with pre-existing hepatic disease or conditions that increase cardiac arrhythmia risk is also restricted and requires close monitoring.
Pregnancy/Lactation Status Restricted/Not Recommended. Use during pregnancy is generally avoided for non-life-threatening conditions; prolonged, high-dose use in the first trimester is prohibited. Breastfeeding is not recommended for women on repeated or long-term dosing.
Excipient-Specific Restriction Oral formulations containing lactose may be prohibited in patients with rare hereditary problems like galactose intolerance.

What should I know about interactions with other medicines?

The official regulatory profile for Flucess (Fluconazole) primarily documents pharmacokinetic interactions resulting from its effect on specific liver enzyme systems. Fluconazole is classified as a potent inhibitor of CYP2C9 and CYP2C19, and a moderate inhibitor of CYP3A4. This inhibition significantly raises the plasma exposure (AUC/Cmax) of many co-administered medicinal products metabolized by these enzymes.

Absolute Contraindications

Co-administration of Flucess is strictly prohibited with several medicinal products due to the officially documented risk of severe cardiac events, primarily QT interval prolongation. This contraindicated list includes Astemizole, Cisapride, Pimozide, Quinidine, and Erythromycin. Co-administration with Terfenadine is also prohibited when the Fluconazole dose is 400 mg/day or greater.

Clinically Significant Interactions

Interactions leading to substantially increased exposure include those with anticoagulants like Warfarin, which may increase bleeding risk, and immunosuppressants such as Cyclosporine, Tacrolimus, and Sirolimus. Fluconazole may also increase the plasma levels of certain oral hypoglycemics (e.g., Glipizide, Tolbutamide). Conversely, the co-administration of Rifampicin (Rifampin) is documented to reduce Fluconazole's systemic exposure. A pharmacodynamic risk is noted with other QTc-prolonging agents, such as Amiodarone, due to a potential additive effect on the QT interval. Official data confirms Fluconazole absorption is not affected by food or antacids, negating administration-timing constraints related to meals. Interaction consequences may be more pronounced in patients with renal impairment.

Mechanism of Action

Targeted Blockade of Fungal Ergosterol Synthesis

Fluconazole acts as a highly selective competitive inhibitor of the essential fungal enzyme Lanosterol 14-alpha demethylase (L14-DM). This enzyme, a cytochrome P450-dependent protein, is crucial for the synthesis of fungal structural components. By binding to the enzyme's heme iron, the drug blocks the metabolic conversion of lanosterol into ergosterol, the key sterol necessary for fungal cell membrane structure. This targeted blockade initiates a cascade that alters the pathogen's structural integrity.


Cellular Cascade Leading to Membrane Destabilization

The inhibition of L14-DM causes a dual physiological consequence within the fungus: ergosterol depletion and the simultaneous accumulation of toxic 14-alpha-methylated sterols. This combination increases the fluidity and permeability of the fungal cell membrane, resulting in the loss of structural function and integrity. This loss of cellular control prevents the fungus from properly maintaining its internal environment and results in a fungistatic effect, which is characterized by the inhibition of cell replication.


Biological Limits to Mechanism Efficacy

Drug effectiveness is constrained by resistance mechanisms, including mutations in the ERG11 gene that alter the L14-DM target structure, reducing the drug's affinity, and the overexpression of efflux pumps (e.g., CDR and MDR transporters) that actively transport the drug out of the fungal cell. These constraints prevent sufficient intracellular concentrations from being achieved to exert effective inhibition of the target enzyme.

Dosage and Administration Information

How Flucess is Used: Official Administration Guidelines

The administration of Flucess (fluconazole) is strictly guided by the official instructions provided in regulatory documents, ensuring the medicine is used according to its approved systemic profile. This section details the correct routes, official dosing patterns, and specific conditions for use, without covering indications or safety.

Approved Administration Routes

Flucess is available for systemic administration through two primary routes:

  • Oral (PO): Via capsules, tablets, or oral suspension.
  • Intravenous (IV) Infusion: Via solution for injection, typically utilized when oral administration is not possible. The daily dose remains the same regardless of the route chosen.

Official Dosage and Administration Conditions

Use Parameter Regulatory Instruction (Adults) Notes
Dosing Principle A loading dose (twice the daily maintenance dose) is generally administered on Day 1 for multi-dose regimens. Speeds attainment of systemic levels.
Standard Daily Range Maintenance doses typically range from 100 mg to 400 mg once daily, based on the specific condition. Single oral dose of 150 mg is used for acute vaginal candidiasis.
Timing Relative to Food Oral forms can be taken with or without food. Food does not impact drug absorption.
IV Administration Rate Infusion must not exceed 10 mL per minute (equivalent to 200 mg/hour). IV administration must be slow and continuous.

Population-Specific Use Adjustments

Population-Specific Use Adjustments

Dosing regimens must be modified for certain populations, particularly those with compromised kidney function. For patients receiving multiple doses with reduced kidney function (creatinine clearance le 50 mL/min), the subsequent daily dose after the loading dose is typically reduced by 50%. Patients undergoing hemodialysis are typically instructed to receive 100% of the recommended dose after each dialysis session.

Recent Clinical Evidence

Research evidence / Overview of Studies for Flucess

Evidence for Systemic and Invasive Fungal Infections (Candidiasis, Cryptococcal Meningitis)

Research has studied Flucess for severe and deep-seated fungal infections, including invasive candidiasis and cryptococcal meningitis. These studies often included Randomized Controlled Trials (RCTs) applied in research contexts involving critically ill patients and those with compromised immune systems. Studies monitored outcomes related to fungal clearance and overall survival over a defined time interval. Findings describe patterns observed in the studies related to mycological eradication. Studies note that inherent resistance in certain fungal types, like C. glabrata, is a documented challenge when interpreting trial outcomes. Research has yielded limited data on the long-term functional status of patients after recovery from severe systemic infections.

Evidence for Mucosal Fungal Infections

Flucess was also studied for conditions characterized by episodic manifestations, specifically fungal infections of the mucous membranes, such as oropharyngeal, esophageal, and vaginal candidiasis. These were mainly short-term RCTs, and studies monitored outcomes related to symptom resolution and fungal clearance. Research examined the time taken for symptom resolution and findings describe patterns observed in the studies regarding relapse and re-infection in certain subgroups. Uncertainty remains regarding the long-term impact of potential fungal resistance on treatment success for recurrent infections.

Evidence for Prevention (Prophylaxis) of Fungal Infections

Studies explored the use of Flucess in a preventive capacity (prophylaxis) to reduce the risk of developing a severe fungal infection in high-risk groups, such as transplant recipients and very low birth weight infants. Studies report how the occurrence of subsequent invasive fungal infection (IFI) evolved in the observed populations. Findings related to the effect on overall patient mortality were mixed, and results were inconsistent across some trials. Certainty remains low for the uniform observation of survival benefits across all prophylactic settings.

What is Still Uncertain About Flucess

The scientific literature identifies several important areas where research is ongoing and certainty remains low. One primary concern relates to the long-term implications of reduced fungal susceptibility (resistance) that may develop over time. Additionally, while many studies have been conducted, evidence quality varies across studies, and comparative evidence is lacking in several areas to fully explore usage patterns. Research provides context but not individual predictions; findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America (IDSA)
  2. Guidelines for Diagnosing, Preventing and Managing Cryptococcal Disease Among Adults, Adolescents and Children Living with HIV - WHO (2022 Update)
  3. Cryptococcosis: Adult and Adolescent Opportunistic Infections - NIH Clinical Guidelines

Frequently Asked Questions (FAQ)

Common questions about Flucess (FAQ)

Q: Is Flucess used to treat a short-term illness or a chronic (long-term) condition?

Regulatory documents state that Flucess is approved for use in both short-term and long-term treatments. For example, it is used as a single dose for acute conditions, but also for long-term suppressive/maintenance therapy for certain deep-seated infections. The duration of use is determined by the specific fungal condition being addressed.

Q: Is Flucess generally known to cause drowsiness or affect concentration?

Official product information lists effects such as dizziness, insomnia, and somnolence (drowsiness) among documented side effects. For this reason, official labels contain a warning advising caution regarding driving or operating machinery if dizziness or seizures are experienced.

Q: Will Flucess cause a noticeable change in blood pressure or heart rate?

Regulatory warnings highlight the risk of serious heart rhythm changes, specifically QT interval prolongation and Torsade de pointes. While these conditions affect the heart’s electrical activity, general changes in blood pressure or a common increase in heart rate are not typically listed among the common adverse effects.

Q: Are there any long-term studies available on the use of Flucess?

Regulatory texts reference studies of varied durations, including those focusing on long-term maintenance or suppressive therapy for specific infections. However, official documents also note that there may be limited data on certain functional or resistance-related long-term outcomes.

Q: Does Flucess affect the ability to drive or operate machinery?

Official documentation notes that if symptoms such as dizziness or seizures occur, caution is advised regarding driving or operating heavy machinery. This information is based on the known central nervous system side effects of the medication.

Q: How is Flucess metabolized or processed by the body?

According to the official clinical pharmacology information, Flucess is primarily processed by the kidneys through a process called renal excretion. Approximately 80% of the administered dose appears in the urine as the unchanged drug, meaning the kidneys are the main system for clearing the medicine from the body.

Q: What is the earliest a patient may need to consider an adjustment to Flucess?

Adjustments to the prescribed amount are often required on Day 1 of a multi-dose regimen through the use of a loading dose. Additionally, official instructions specify the need for a dosage adjustment in patients who have pre-existing reduced kidney function.

Q: Is there a particular organ system most affected by Flucess?

Official warnings highlight the potential for serious effects on two major organ systems. These are hepatic toxicity (damage to the liver) and serious cardiac effects (abnormalities in heart rhythm). Both systems require close monitoring during treatment.

Q: What does 'contraindication' mean in the context of Flucess?

A contraindication is a term used in regulatory documents to indicate a circumstance under which the medicine is prohibited from being used. For Flucess, this includes known hypersensitivity (severe allergic reaction) and co-administration with a specific list of prohibited medications.

Q: What safety class is Flucess categorized under for pregnant or breastfeeding individuals?

Under the current US labeling system (PLLR), the medicine does not use the old letter categories (A, B, C, D, X). Instead, the label provides detailed risk summaries for Pregnancy, Lactation, and Females/Males of Reproductive Potential. These sections describe the data available on risk rather than providing a single classification letter.

Q: Is it still necessary to take Flucess if symptoms improve completely?

Regulatory patient guidelines generally describe the importance of continuing the prescribed full course of treatment, even if symptoms improve. This approach is intended to ensure full fungal clearance and reduce the risk of the infection returning.

Q: What if a person is already taking a medicine that has a known interaction with Flucess?

Official warnings strictly identify known interactions and contraindications. For medicines that are absolutely prohibited (contraindicated), co-administration is strictly excluded by regulatory documents. For other interacting medicines, the regulatory information implies that close patient monitoring or dosage adjustments may be necessary to manage safety risks.

Q: What official documents describe the mechanism of action for Flucess?

The detailed explanation of how Flucess works to halt fungal growth is described in authoritative documents. This information can be found in the Clinical Pharmacology section of the FDA label and the Pharmacodynamic Properties section of the EMA Summary of Product Characteristics (SmPC).

Q: Is it normal to feel anxious or restless when first starting Flucess?

Official documents from some health authorities list nervousness as an uncommon adverse effect. While nervousness is not the same as anxiety or restlessness, the classification suggests that some individuals may experience related feelings that affect their mood or state of calm.

Q: What should be done if a suspected interaction occurs between Flucess and another drug?

Regulatory documents require close patient monitoring and the reporting of adverse events when drug interactions are involved. If a suspected reaction or interaction occurs, the official guidance confirms the need for immediate medical evaluation.

Q: Is there a specific time of day that is considered optimal for taking Flucess?

Official instructions state the medicine can be taken once a day, and it can be taken with or without food. No specific time of day, such as morning or evening, is typically required for the medication to be effective, focusing instead on consistent daily administration.

Q: Can Flucess be used by older adults (e.g., those over 65)?

Yes, official labels include pharmacokinetic data specifically for older adults (those 65 years and older), which confirms established use in this population. Dosage adjustments may be necessary for older adults, particularly those with changes in kidney function.

Q: Does Flucess have an impact on fertility or reproductive health?

Regulatory documents state that non-human studies have indicated a potential effect on male fertility. However, the official documents also note that human studies on the impact on male or female fertility are either limited or lacking.

Q: What are the non-directive guidelines for missing a single dose of Flucess?

The standard patient information describes a process where, if a dose is missed, taking it as soon as the person remembers is an option. However, if it is almost time for the next scheduled dose, the advice is usually to skip the missed dose and resume the normal schedule.

Q: Can Flucess be taken alongside common cold or flu medicines?

The label lists specific known contraindicated and interacting drugs, but common over-the-counter cold and flu medicines are not prohibited as a general group. Caution is advised with all combination products, and awareness of active ingredients in co-administered medicines is important.

Q: How is the safety of Flucess monitored after it is released to the public?

Official documents confirm that the medicine's safety is continuously monitored after release through a process called post-marketing surveillance. Healthcare professionals are also specifically asked to report suspected adverse reactions so that safety data can be continually updated and evaluated.

Q: Do official documents mention a maximum duration for the use of Flucess?

Official documents list specific treatment durations for each approved indication. These durations vary widely, ranging from a single dose for certain acute infections up to several months, or sometimes even lifelong suppressive therapy for severe conditions.

How should Flucess be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory guidelines strictly define the conditions for storing and disposing of this medication. This information is based on labeled instructions from government health authorities.

Storage Constraints:

Product Form Temperature Range Stability/Protection
Capsules/Dry Powder At or below 30 C Keep in a cool, dry place.
Reconstituted Suspension Between 2 C and 30 C Discard after 14 days; Do not freeze.

All forms of the medicine must always be kept out of the reach of children. The product should be stored in its original container and protected from excess heat, moisture, and direct sunlight.

Disposal Protocol:

Unused or expired medicine should preferably be disposed of through a dedicated drug take-back program. If a take-back program is unavailable, mix the medicine with an unappealing substance, such as dirt or used coffee grounds, seal it in a container, and place it in the household trash. Do not flush the medication down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flucess found in:

A-Z Index: